Susan Froshauer (former CEO CURE, co-founder Rib-X Pharmaceuticals)

New Haven
District New Haven - 470 James St, Suite 1 New Haven, 06513
May 3, 2018, 5:30 p.m.

About this event

Susan Froshauer served as President and CEO of CURE (now BioCT) from 2013 through Oct 2017. BioCT provides education, entrepreneurial resources, and advocates on behalf of the bioscience industry in Connecticut.

Today, she is VP of CURE Collaborations, LLC, a leader of the CURE Commons accelerator programs, and an Entrepreneur in Residence at Yale’s Office of Cooperative Research. She is also a board member of Carogen, LambdaVision, Bioxiness, Thames River Innovation Partners.

Earlier in her career she was a co-founder and CEO of Rib-X Pharmaceuticals (now Melinta). During her 11 year tenure she led the company through $160mm of investment and development of novel antibiotic treatments.

Susan received a Ph.D. in Microbiology and Molecular Genetics from Harvard University and a B.A. from Connecticut College. Earlier in her career she served as a Research Scientist and Licensing Executive at Pfizer.

Please see the Parking Map for parking directions.

Speaker

Susan Froshauer (former CEO CURE, co-founder Rib-X Pharmaceuticals)

Susan Froshauer

CURE

Susan served as President and CEO of CURE (now BioCT) from '13 through Oct '17. Today she's a leader of the CURE Commons accelerator programs, an EIR at Yale OCR and a board member and advisor to many bioscience companies. She led Rib-X Pharmaceuticals (now Melinta) as CEO and cofounder for 11 years, raising $160mm in capital and guiding the development of novel antibiotic treatments.

Read More

When

May 3, 2018
5:30 p.m. - 8:30 p.m.

Where

District New Haven
470 James St, Suite 1 New Haven06513

Brought to you by

Nicholas Caplan

Nicholas Caplan

New Haven Chapter Director
View Profile